Deng's research demonstrated that NEK2 binds β-catenin, blocking the interaction between NEK2 and the destruction complex; ultimately contributing to sorafenib resistance in hepatocellular carcinoma 20. Here, NEK2 is linked to hepatocellular carcinoma.